通过临床药剂师干预,减少住院儿科癌症患者的药物相关问题:土耳其的一项干预研究
Ömer Faruk Özkanlı1, Ahmet Koç2, Nurşah Eker2
1Department of Clinical Pharmacy, Marmara University Faculty of Pharmacy, Istanbul, Türkiye.
概括
临床药剂师通过实施建议,显著减少了儿科瘤患者的药物相关问题. 这项干预措施改善了血液瘤诊所的药物安全性和患者护理.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 临床药房 临床药房
背景情况:
- 临床药剂师在管理抗癌疗法方面至关重要,包括治疗方案审查,剂量计算和不良事件监测.
- 与药物相关的问题 (DRPs) 对患有瘤疾病的患者构成重大风险.
研究的目的:
- 在住院的儿科癌症患者中识别,分类和减少DRPs.
- 评估临床药剂师干预对DRP和药物安全性的影响.
主要方法:
- 一个前性,干预性研究,进行了五个月 (2024年4月至8月).
- 使用药品护理网络版本 9.1.1. 来识别和分类DRP.
- 在干预期间,临床药剂师向医疗保健团队提出了临床药剂师建议.
主要成果:
- 在80名儿科瘤患者中检测到总共457个DRP.
- 在干预期间,DRP的频率下降了56.3% (p < 0.001).
- 临床药剂师的建议,主要是关于剂量调整和使用说明,医生100%接受.
结论:
- 住院的儿科瘤患者经历了DRP的高发病率.
- 临床药剂师的干预措施在减少DRP和改善药物安全方面是有效的.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
Drug Dosing: Infants and Children
255
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
255
Therapeutic Drug Monitoring: Affecting Factors
201
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
201


